Press Release – SinoMab BioScience

All

2022-04-20

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

2022-03-14

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

2022-02-16

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

2022-02-07

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-01-11

SinoMab Awared the “Best Small and Mid-Cap Company” and “Best CEO” and the “Listed Company with the Most Growth Potential”

2021-11-30

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

2021-11-25

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

2021-09-17

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

2021-05-26

SinoMab Awarded ''Most Outstanding Biopharmaceutical Company of the Year''

2021-01-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

2020-11-23

SinoMab Commenced Construction of its China Headquarters

2020-06-24

SinoMab Acquired a Land Parcel of 43,333 sq.m. in Suzhou Industrial Park

2020-06-10

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress

2020-03-24

SinoMab Announced 2019 Annual Results

2020-01-10

SinoMab Granted the Most Popular Newly Listed Company Award

2019-11-29

SinoMab BioScience Successfully Listed on Main Board of SEHK

2019-11-20

Sinomab BioScience Announces Latest Progress of its Drug Candidate SM03

2019-11-11

Sinomab BioScience Was Over-Subscribed by approximately 11.87 Times for HKPO

2019-10-30

SinoMab BioScience Limited Announces Proposed Listing on Main Board of HKEx

2022

2022-04-20

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

2022-03-14

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

2022-02-16

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

2022-02-07

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-01-11

SinoMab Awared the “Best Small and Mid-Cap Company” and “Best CEO” and the “Listed Company with the Most Growth Potential”

2021

2021-11-30

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

2021-11-25

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

2021-09-17

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

2021-05-26

SinoMab Awarded ''Most Outstanding Biopharmaceutical Company of the Year''

2021-01-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

2020

2020-11-23

SinoMab Commenced Construction of its China Headquarters

2020-06-24

SinoMab Acquired a Land Parcel of 43,333 sq.m. in Suzhou Industrial Park

2020-06-10

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress

2020-03-24

SinoMab Announced 2019 Annual Results

2020-01-10

SinoMab Granted the Most Popular Newly Listed Company Award

2019

2019-11-29

SinoMab BioScience Successfully Listed on Main Board of SEHK

2019-11-20

Sinomab BioScience Announces Latest Progress of its Drug Candidate SM03

2019-11-11

Sinomab BioScience Was Over-Subscribed by approximately 11.87 Times for HKPO

2019-10-30

SinoMab BioScience Limited Announces Proposed Listing on Main Board of HKEx